RxDoctor Payments Data

Leslie Willingham, MD

Family Medicine · Tucson, AZNPI 1174787790

Payments from drug & device makers

$5,809in general payments, 2019–2025

Across 356 payments — averaging $16.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$803
  • Novo Nordisk$618
  • Amgen$458
  • AstraZeneca$386
  • Pfizer$371
  • Lilly USA, LLC$312
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$5,809100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,809 in reported general payments places this provider in the 90th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$121,581
Medicare patients
405
Services billed
7,957

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban83$92,750
OzempicSemaglutide61$89,986
JardianceEmpagliflozin39$58,326
TrulicityDulaglutide33$46,175
MyrbetriqMirabegron44$41,891
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$40,694
FarxigaDapagliflozin Propanediol45$38,332
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog24$26,756
RybelsusSemaglutide19$25,551
ProliaDenosumab14$24,446
MounjaroTirzepatide14$22,277
XareltoRivaroxaban12$20,157
JanuviaSitagliptin Phosphate12$19,388
Breo ElliptaFluticasone/Vilanterol19$8,979
MovantikNaloxegol Oxalate21$8,592

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$618$115,53780 claims
PfizerEliquis, Premarin$371$100,16895 claims
Lilly USA, LLCTrulicity, Mounjaro$312$68,45247 claims
Boehringer IngelheimJardiance$130$58,32639 claims
GSKTrelegy Ellipta, Breo Ellipta$257$49,67461 claims
Astellas Pharma US IncMyrbetriq$96$41,89144 claims
AstraZenecaFarxiga$386$38,33245 claims
AmgenProlia$458$24,44614 claims
MerckJanuvia, Lagevrio (Eua)$71$21,34923 claims
Johnson & JohnsonXarelto$287$20,15712 claims
AbbVieSynthroid$803$5,20470 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →